MedinCell S.A./€MEDCL
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About MedinCell S.A.
MedinCell S.A. is a pharmaceutical company focused on the development of long-acting injectable therapeutics. Operating in the healthcare industry, MedinCell specializes in drug delivery technology that combines global health needs with the potential for improved patient adherence. The company is known for its proprietary BEPO technology, which allows for controlled and sustained release of medication. Founded in 2002 and headquartered in Jacou, France, the company works on a pipeline of therapeutic solutions across various segments, including pain management, contraception, and mental health. MedinCell's strategic position is reinforced by its collaborative partnerships and its innovative approach to addressing unmet medical needs with affordable healthcare solutions.
Ticker
€MEDCL
Sector
Primary listing
PAR
Employees
131
Headquarters
Website
MedinCell S.A. Metrics
BasicAdvanced
€644M
-
-€0.62
1.11
-
Price and volume
Market cap
€644M
Beta
1.11
52-week high
€19.71
52-week low
€12.00
Average daily volume
59K
Financial strength
Current ratio
2.699
Quick ratio
2.663
Long term debt to equity
-366.762
Total debt to equity
-411.328
Interest coverage (TTM)
-2.12%
Profitability
EBITDA (TTM)
-10.071
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-66.50%
Operating margin (TTM)
-38.81%
Effective tax rate (TTM)
-0.88%
Revenue per employee (TTM)
€210,000
Management effectiveness
Return on assets (TTM)
-10.56%
Return on equity (TTM)
64.48%
Valuation
Price to revenue (TTM)
20.842
Price to book
-39.29
Price to tangible book (TTM)
-33.82
Price to free cash flow (TTM)
32.456
Free cash flow yield (TTM)
3.08%
Free cash flow per share (TTM)
0.601
Growth
Revenue change (TTM)
132.12%
Earnings per share change (TTM)
-29.38%
3-year revenue growth (CAGR)
49.26%
3-year earnings per share growth (CAGR)
-14.63%
Bulls say / Bears say
Teva Pharmaceutical's Q2 2025 sales of its branded schizophrenia drug Uzedy climbed 120% year-over-year to $54 million. As a result, Teva raised its full-year 2025 sales forecast for Uzedy to $190–$200 million, significantly improving MedinCell's potential royalty revenues. (Reuters)
MedinCell has entered a strategic co-development and licensing deal with AbbVie that includes an upfront payment of $35 million and potential milestone and commercialization payments of up to $1.9 billion. This agreement diversifies MedinCell’s pipeline funding and helps lower R&D risk. (WSJ)
In February 2025, the European Investment Bank permanently lifted two financial covenants tied to MedinCell’s €40 million loan, removing both the gearing and debt service ratio requirements. This demonstrates the lender’s confidence in MedinCell’s financial stability. (Dow Jones Newswires)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MedinCell S.A. stock?
MedinCell S.A. (MEDCL) has a market cap of €644M as of September 14, 2025.
What is the P/E ratio for MedinCell S.A. stock?
The price to earnings (P/E) ratio for MedinCell S.A. (MEDCL) stock is 0 as of September 14, 2025.
Does MedinCell S.A. stock pay dividends?
No, MedinCell S.A. (MEDCL) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next MedinCell S.A. dividend payment date?
MedinCell S.A. (MEDCL) stock does not pay dividends to its shareholders.
What is the beta indicator for MedinCell S.A.?
MedinCell S.A. (MEDCL) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.